- Home
- ADIL vs KPRX Comparison
ADIL vs KPRX Comparison
Compare ADIL & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- KPRX
- Stock Information
- Founded
- ADIL 2010
- KPRX 1998
- Country
- ADIL United States
- KPRX United States
- Employees
- ADIL N/A
- KPRX N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ADIL Health Care
- KPRX Health Care
- Exchange
- ADIL Nasdaq
- KPRX Nasdaq
- Market Cap
- ADIL 7.6M
- KPRX 7.9M
- IPO Year
- ADIL 2018
- KPRX N/A
- Fundamental
- Price
- ADIL $0.38
- KPRX $2.36
- Analyst Decision
- ADIL Strong Buy
- KPRX Strong Buy
- Analyst Count
- ADIL 1
- KPRX 1
- Target Price
- ADIL $8.00
- KPRX $10.00
- AVG Volume (30 Days)
- ADIL 4.2M
- KPRX 62.2K
- Earning Date
- ADIL 08-19-2025
- KPRX 08-08-2025
- Dividend Yield
- ADIL N/A
- KPRX N/A
- EPS Growth
- ADIL N/A
- KPRX N/A
- EPS
- ADIL N/A
- KPRX N/A
- Revenue
- ADIL N/A
- KPRX N/A
- Revenue This Year
- ADIL N/A
- KPRX N/A
- Revenue Next Year
- ADIL N/A
- KPRX N/A
- P/E Ratio
- ADIL N/A
- KPRX N/A
- Revenue Growth
- ADIL N/A
- KPRX N/A
- 52 Week Low
- ADIL $0.22
- KPRX $2.25
- 52 Week High
- ADIL $1.30
- KPRX $4.29
- Technical
- Relative Strength Index (RSI)
- ADIL 43.03
- KPRX 25.07
- Support Level
- ADIL $0.39
- KPRX $2.25
- Resistance Level
- ADIL $0.46
- KPRX $3.29
- Average True Range (ATR)
- ADIL 0.08
- KPRX 0.16
- MACD
- ADIL -0.01
- KPRX -0.06
- Stochastic Oscillator
- ADIL 7.29
- KPRX 12.22
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.